Chikungunya fever (CF) is caused by an arbovirus which is transmitted through Aedes mosquitoes. It is a single stranded RNA virus belonging to the Alphavirus genus of the Togaviridae, the characteristic feature of the family of this virus is they are mostly transmitted by arthropods. In 1952-1953 Tanzania had the outbreak for the first time and samples of both man and mosquitoes contained the virus. The virus is heat labile in nature and is found to be sensitive to temperatures above 580 Celsius. The virus uses Aedes aegypti mosquitoes as the common vector for transmitting the infection in urban areas and Aedes albopictus transmits in the rural areas.
Considering the epidemiology of the disease, it is mostly observed in the South-East Asia region and a human-mosquito-human transmission cycle is observed which is different from that of the sylvatic transmission cycle described on the African continent. A high vector density is observed during the post monsoon season which increases the transmission. Chikungunya fever epidemics display cyclical and seasonal trends. During the post monsoon period human beings serve as the Chikungunya virus reservoir, whereas, during inter-epidemic periods, vertebrates like monkeys, rodents, birds, and others get affected.
The clinical features observed in the chikungunya virus are fever (92%) usually associated with arthralgia (87%), backache (67%) and headache (62%). Low or high grade fever reaching 39 to 40 Degrees Celsius, with shaking chills and rigors can be observed that lasts for 24 to 48 hours and the use of antipyretics can subside it. Patients may also have arthralgia without fever where the joint pain worsens in the morning and can be relieved by mild exercise. It may get remited for 2-3 days and then reappear in a saddle back pattern. Migratory polyarthritis with effusions can also be observed in 70% cases, but resolves in the majority. Joints like ankles, wrists and small joints of the hand are worst affected. The classical bending phenomenon may occur due to the lower limb and back involvement, this makes the patient stoop down and bend forward.
The three phases of chikungunya infection are acute phase (less than 3 weeks), sub-acute phase (> 3 weeks to 3 months), chronic phase (> 3 months) and the clinical presentation can be mild, moderate or severe depending upon the symptoms. Other clinical features include mucocutaneous manifestation where transient maculopapular rash is observed in 50 % patients. Also angiomatous lesions, purpuras, stomatitis, oral ulcers, nasal blotchy erythema are observed in the patients. Apart from this, exfoliative dermatitis, epidermolysis bullosa and ocular manifestation can be observed. Ocular manifestations including photophobia and retro-orbital pain may also be seen. Neuroretinitis and uveitis in one or both eyes are also observed in patients.
1.
Le cancer et le COVID ont conduit le patient à une double transplantation de poumon.
2.
Effective for localizing small, non-palpable breast lesions is ultrasound-guided localization with magnetic seeds.
3.
Long-term study links chronic conditions in midlife to higher cancer risk and mortality
4.
Subcutaneous Cancer Immunotherapies Provide New Options for Physicians and Patients
5.
When does a melanoma metastasize? Implications for management
1.
Unlocking the Mysteries of Reticulocyte Counts: A Guide to Understanding Your Blood Results
2.
The Checkpoint Architect: Unraveling the Mechanisms of PD-L1 Regulation for the Next Generation of Small-Molecule Therapies
3.
Screening Efficacy, Molecular Precision, and Therapeutic Revolutions in Lung Cancer 2025
4.
Genetic Testing in Cancer Prevention: BRCA Mutations and Lynch Syndrome Unlocked
5.
Transforming Cancer Care: CAR T-Cell Therapy for Relapsed/Refractory NHL and ALL
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
3.
An In-Depth Look At The Signs And Symptoms Of Lymphoma
4.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part IV
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation